Neurobiološke osnove ovisnosti o alkoholu by Ana Matošić et al.
134 Acta Clin Croat,  Vol. 55,   No. 1,  2016
Acta Clin Croat 2016; 55:134-150 Review
doi: 10.20471/acc.2016.55.01.19
NEUROBIOLOGICAL BASES OF ALCOHOL ADDICTION 
Ana Matošić1, Srđan Marušić1, Branka Vidrih1, Ana Kovak-Mufić1 and Lipa Čičin-Šain2
1Clinical Department of Psychiatry, Sestre milosrdnice University Hospital Center; 2Ruđer Bošković Institute, 
Zagreb, Croatia
SUMMARY – Alcohol addiction is a heterogeneous psychiatric disorder according to both phe-
notype and etiology. Difference in phenotype characteristics manifests in the manner the addiction 
arises, history of the alcoholic and history of drinking, comorbid disorders, and the phenomenon 
of abstinence difficulties. Concerning the etiology of alcoholism, the disease itself is considered 
to be a consequence of an interactive influence of the environment and genetic factors. Numero-
us researches conducted in the last decades discovered many aspects of the biochemical, cell and 
molecular bases of alcohol addiction, leading to a conclusion that alcoholism is, like many other 
addictions, a brain disease. By recognizing alcoholism as a disease which basically implies changes 
of the neurobiological mechanisms, as well as a clear genetic basis, it was supposed that the dise-
ase, having its basis solely in the symptomatology, is essentially heterogeneous. By trying to solve 
the problem of a clinically heterogeneous nature of the disease during the last fifty years, various 
sub-classifications of such patients have been suggested. According to Cloninger, subtypes of alco-
holism differ also according to changes in the brain neurotransmission systems, i.e. it is supposed 
that patients suffering from alcoholism type 1 have a more pronounced dopaminergic transmission 
deficit, while dopaminergic transmission is not disturbed significantly in patients diagnosed with 
alcoholism type 2, who, however, have a significant lack of serotonergic transmission. In such a way, 
Cloninger actually presented the basis of the so-called neurobiological alcoholism model. Since he 
has connected differences in neurotransmission with differences in personality characteristics, this 
model is also known as the psychobiological model of alcoholism. The characteristic of alcoholism 
type 1 is avoiding damage (Harm Avoidance, HA) decreased dopamine transmission and incre-
ased serotonin transmission, while the significant characteristic of alcoholism type 2 is seeking 
for excitement (Novelty Seeking, NS), unchanged dopamine transmission and decreased serotonin 
transmission. These neurochemical differences among alcoholism subtypes represent the basis for 
a different therapy approach. Intake of alcohol changes different gene expression in the human 
brain. The inheritance model of alcoholism is not fully explained, however, it is considered that the 
disease is connected to a larger gene number included in neurotransmission, cell mechanisms and 
general metabolic function, with a simultaneous influence of the environment. The contribution 
of genetic factors is stronger in certain types of alcoholism and thus we have been confronted in 
the last years of alcoholism research with studies researching the connections of some alcoholism 
subtypes with the polymorphism phenomenon in the genes coding the synaptic proteins included 
in the alcoholism etiology. The primary role of monoamine oxidase (MAO) in the brain is catalysis 
of deamination of the oxidative neurotransmitter amines, i.e. serotonin, adrenaline, noradrenaline 
and dopamine. Thus, this enzyme is the key factor for maintaining cytoplasmic concentration of 
various neurotransmitters and for regulation of the neurotransmitting synaptic activity. Taken this 
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MAO function into consideration, MAO is the enzyme included in the etiology and pathogenesis 
of various neuropsychiatric and neurological disorders. The finding of the decreased platelet MAO 
activity in various psychiatric disorders has brought us to the assumption that this enzyme may be a 
constitutional/genetic indicator (trait marker) or an indicator of disease condition (state marker) in 
biologic psychiatry. There are only a few studies of alcohol addiction researching the connections of 
the MAO coding gene polymorphism and alcoholism; however, these studies are primarily related 
to the variable number of tandem repeats (VTNR) polymorphism in the regulatory gene region for 
MAO-A, considered to influence the transcription activity/functionality of the enzyme.
Key words: Alcoholism – genetics; Alcoholism – physiopathology; Genetic predisposition to disease; Mo-
noamine oxidase – blood; Phenotype; Polymorphism, genetic 
Definition, Etiology and Epidemiology of 
Alcoholism
Alcohol addiction is a psychiatric disorder in which 
long-term abuse of alcohol drinks leads to mental and 
bodily disorders, disturbed social relations, as well as 
economic difficulties. This definition was given by the 
World Health Organization (WHO) in Copenhagen 
some fifty years ago and has remained unchanged 
down to the present day in spite of various objections 
by experts related to the duration and intensity of al-
cohol abuse, as well as the gravity of associated dis-
orders.
In order to set an exact diagnosis, we currently use 
two types of operative criteria, i.e. Diagnostic and 
Statistical Manual of Mental Disorders, 5th ed. (DSM 
V) and International Classification of Diseases and 
Relating Conditions, 10th revision (ICD 10), whereby 
we differ alcohol abuse and alcohol addiction (alcohol 
dependence)1,2. In our clinical practice, it is recom-
mended to use the ICD 10 classification, this being at 
the same time the WHO official classification. 
As stated above, diagnostic criteria based on the 
mentioned classifications currently are important to 
set a correct diagnosis; however, alcoholism is a com-
plex condition involving a variety of mental, physical, 
behavioral and cognitive changes caused by excessive 
intake of alcohol3,4. Considering behavioral chang-
es, it is characteristic that our attention is drawn to 
drinking of alcohol in the first place while neglecting 
all other interests and satisfactions. Changes in the 
Table 1. Criteria for setting the diagnosis of dependence syndrome (according to ICD 10)
A definitive diagnosis of dependence should usually be made only if three or more of the following have been 
present together at some time during the previous year:
(a) a strong desire or sense of compulsion to take the substance;
(b) difficulties in controlling substance-taking behavior in terms of its onset, termination, or levels of use;
(c) a physiological withdrawal state (see F1x.3 and F1x.4) when substance use has ceased or been reduced, as 
evidenced by: the characteristic withdrawal syndrome for the substance; or use of the same (or a closely related) 
substance with the intention of relieving or avoiding withdrawal symptoms;
(d) evidence of tolerance, such that increased doses of the psychoactive substances are required in order to achieve 
effects originally produced by lower doses (clear examples of this are found in alcohol- and opiate-dependent 
individuals who may take daily doses sufficient to incapacitate or kill nontolerant users);
(e) progressive neglect of alternative pleasures or interests because of psychoactive substance use, increased amount of 
time necessary to obtain or take the substance or to recover from its effects;
(f ) persisting with substance use despite clear evidence of overtly harmful consequences, such as harm to the liver 
through excessive drinking, depressive mood states consequent to periods of heavy substance use, or drug-related 
impairment of cognitive functioning; efforts should be made to determine that the user was actually, or could be 
expected to be, aware of the nature and extent of the harm.
ICD-10 = International Statistical Classification of Diseases and Related Health Problems 10th Revision
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central nervous system occur and manifest as a phe-
nomenon of alcohol tolerance, signs of physical ad-
diction and craving for alcohol, followed by loosing 
drinking control. 
Table 1 shows diagnostic criteria according to the 
ICD 10 classification for setting the diagnosis of alco-
hol addiction. At least three of the six criteria should 
be present to set the clinical diagnosis of alcoholism.
Next to these diagnostic criteria, clinical practice 
and research also use various measuring instruments 
(scales) serving as assistance when evaluating the pa-
tient’s profile, establishing drinking pattern, problems 
in persons that have not yet become addicted, etc. In 
most cases, we speak of shorter or longer question-
naires filled in either by the physician or by the patient 
himself/herself. There are more than 100 such ques-
tionnaires, e.g., Alcohol Use Disorders Identification 
Test (AUDIT), Michigan Alcohol Screening Test 
(MAST), Brief Drinker Profile (BDP), Severity of 
Alcohol Dependence Questionnaire (SADQ ), Short 
Alcohol Dependent Data (SADD), and others.
Accordingly, one should consider alcohol addic-
tion as a heterogeneous disorder considering both the 
etiology and phenotype5,6. Differences in phenotype 
characteristics are reflected in the age at addiction on-
set, alcohol disease history and history of drinking, 
comorbid disorders, and occurrence of abstinence dif-
ficulties.
When we speak about alcoholism etiology, it is 
considered that the disease occurs as the consequence 
of an interaction between the environment and ge-
netic factors7-10. Alcohol dependence appears more 
often among people who have been grown up in an 
environment tolerant to drinking of alcohol or with a 
person suffering from a mental disorder11. It has also 
been known for a long time that positive family he-
redity may be a strong indicator for the occurrence 
of dependence12. In children grown up with a person 
suffering from alcoholism, the probability of the dis-
ease occurrence is threefold that in children whose 
parents are free from alcoholism. Studies in twins and 
adopted individuals were conducted to assess the im-
pact of genetic factors. Seven of eight studies of male 
twins established a significantly higher conformity 
with monozygotic than with dizygotic twins11. Adop-
tive studies, the best known of which was performed 
in Stockholm in the 1980s13,14, speak for the fact that 
alcohol dependence is a clinically heterogeneous dis-
order, whereby some forms are more dependent on the 
inheritance, e.g., the form of alcoholism occurring lat-
er in life in a neurotic structure personality (alcohol-
ism type 1) is under a weaker heredity influence (less 
than 40%) as compared with the form of alcoholism 
where the dependence on alcohol develops earlier in 
life, followed by antisocial behavior (alcoholism type 
2) and where the inheritance influence is very strong 
(about 90%). Results of the twins and adoptive studies 
point to the fact that approximately 50%-60% of the 
case-studies concerning alcoholism are connected to 
genetic factors. Taking the paradigm of inheritance 
into consideration, it is established that alcohol ad-
diction is a very complex polygenetic disease where 
genetic influence does not reflect in one gene activity 
effect but in the interactive effect of several ones6,8,13.
Mental disorders and behavioral disorders caused 
by alcohol abuse represent, in regard to stationary hos-
pitalization, the leading psychiatric diagnosis in the 
Republic of Croatia; 21% of all patients admitted in 
2014 were cases of alcoholism, with a 4.6-6.2:1 male 
to female ratio15. Data on the percentage of patients 
addicted to alcohol in the general adult population 
vary depending on the classification or diagnostic cri-
teria applied. Generally, a number of studies report on 
a 6% incidence of alcohol addicts in Croatia, whereas 
in the countries of Western Europe and North Amer-
ica the incidence of alcoholism ranges between 2% 
and 12%16,17. As comorbidity of depressive and anxi-
ety disorders, posttraumatic stress disorder and per-
sonality disorders is well known and often present in 
alcohol addicted patients, it is clear that alcohol addic-
tion poses a major public health problem in Croatia, as 
well as worldwide.
Neurobiological Basis of Alcoholism
Alcohol is a small molecule, water and lipid solu-
ble, and diffuses easily through cell membranes to be 
quickly absorbed in blood. Its breakdown occurs in 
the liver with the help of two enzymes: alcohol dehy-
drogenase (ADH) oxidizes ethanol into acetaldehyde, 
which thereafter, with the help of the enzyme alde-
hyde dehydrogenase (ALDH) transfers into acetate.
Alcohol as a depressor of the nervous system in-
duces sedation, decrease of cognitive and motor func-
tions, etc. Long-term drinking of alcohol brings about 
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a series of psychophysical disorders, followed by the 
loss of neurons in some brain regions (hippocampus, 
cortex) and finally brain atrophy. The grade of brain 
atrophy correlates with the quantity of alcohol taken 
to the body during lifetime18. Alcohol intoxication oc-
curs when the alcohol level in the blood reaches the 
concentration of 50-150 mg/dL, while a concentra-
tion of 400-500 mg/dL is lethal.
The alcohol effect develops through its interaction 
with various membrane proteins, i.e. enzymes, recep-
tors, neurotransmitting and message system trans-
porters, reflecting on the synaptic transmission19,20. 
Thanks to numerous researches and studies dur-
ing the last decades, many of the biochemical, cell 
and molecular bases of alcohol addiction have become 
known, revealing that alcoholism as well as other ad-
dictions are now to be considered as brain diseases20. 
Various addictive substances also result in changes in 
various parts of the brain; however, there is a group 
of brain structures that are affected by all addictive 
substances, i.e. the so-called brain rewarding system, 
a part of the limbic system consisting primarily of the 
tegmentum ventral area (VTA), nucleus accumbens 
(NAc) and prefrontal cortex (PFC), together with the 
pathways connecting them, thus forming the medium 
forebrain bundle (MFB) (Fig. 1). The rewarding sys-
tem acts by interactions of various neurotransmitters, 
e.g., dopamine (FDA), serotonin (SHT), noradrena-
line (NA), GABAergic (GABA), glutamatergic and 
other brain systems. We shall, in short, turn to the 
role of some particular neurotransmitters in alcohol-
ism.
Dopamine 
Dopamine neurons are located in the VTA of the 
mesencephalon and are grouped into several sub-
groups (A8, A9 and A10) sending axons to the NAc, 
PFC, amygdala and the remaining limbic system re-
gions. Precisely, the mesolimbic dopamine has the key 
role in the alcohol addiction enforcement, as well as in 
the rewarding, pleasant effect of drinking alcohol21-23. 
The presence of alcohol activates the dopamine A10 
neurons in VTA, inducing the release of dopamine in 
terminal (projection) areas (NAc, PFC and amygdala) 
and thus increasing dopaminergic neurotransmission. 
The increased dopamine release is felt as a feeling of 
satisfaction24. Changes arising in the postsynaptic 
neurons due to long-term excessive neuron DA activ-
ity gradually lead to changes in the manner in which 
the brain reacts to alcohol. Thus, owing to excessive 
DA availability, the number of dopamine receptors on 
the postsynaptic membrane decreases and the neuron 
decreases its dopamine sensitivity, thus allowing for 
the occurrence of the phenomena such as alcohol tol-
erance, alcohol craving, abstinence disorders, etc.25,26.
Gamma-aminobutyric acid and glutamate
Gamma-aminobutyric acid (GABA) as the main 
inhibition neurotransmitter and glutamate as the 
main excitation neurotransmitter in the brain are also 
included in the modulation effect of alcohol on the be-
havior, thus contributing to the development of alco-
holism. As distinguished from dopamine with its key 
role in the rewarding system, these two neurotrans-
mitters also deserve credit for the sedative effects of 
alcohol, its motor coordination and abstinence symp-
toms involved in some other aspects of alcoholism.
Drinking alcohol brings inhibition of the glutamate 
excitation effect with an increase of the GABAer-
gic inhibition. When we speak of long-term alcohol 
abuse, it leads to self-regulation of transmission, i.e. 
the glutamatergic transmission effect increases with a 
simultaneous decrease in GABA effect. This, again, 
leads to the increased alcohol tolerance. Precisely, this 
neuroadaptation brings about the abstinence phase 
difficulties, followed by an increased sensitivity with 
sweating, anxiety and insomnia27. In animal models, 
it was observed that the GABA-A agonists increased 
and antagonists decreased the intake of alcohol28. 
Serotonin
Serotonergic neurons are found in the raphe cores 
(raphe nuclei, RN) and are projected in practically ev-
ery part of the brain. It is considered that they have a 
significant role in the occurrence of alcohol addiction, 
primarily due to modulation of other neurotransmit-
ting systems, while numerous studies confirm the role 
of SHT in all alcohol addiction aspects. We believe 
today that the lack of serotonergic transmissions leads 
to increased inclination to alcohol intake29-31 and is 
also connected to the impulsive and aggressive be-
havior that is often present in alcohol addicts32,33. This 
especially relates to Cloninger type 2 alcohol addict 
we shall later speak more about34. The decreased SHT 
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transmission is also connected to the individual sensi-
tivity to develop alcoholism9,35,36, while the possibility 
that persons who may be carriers of certain gene vari-
ants coding the SHT transmitters as the main regula-
tor of the serotonin synaptic transmission, and thus 
showing greater vulnerability to alcoholism37 is an is-
sue of special consideration. The connection between 
the activities of the serotonin system and alcohol was 
also shown in animal models, where the level of SHT 
was modified pharmacologically or surgically and the 
effects of this manipulation on various alcoholism as-
pects were observed38,39. 
Noradrenaline
Drinking alcoholic beverages motivates the 
emerging of noradrenergic neurons from the blue core 
(locus coeruleus) and to excessive activity. Elevated 
values of NA and its main metabolite 3-methoxy-4-
hydroxyphenylglycol (MHPG) were found in plasma 
and cerebrospinal fluid of patients suffering from al-
coholism in acute intoxication, as well as when suffer-
ing the abstinence crisis26. It was also shown that the 
basal levels of NA and its metabolite were changed in 
the cortex, hippocampus and limbic system of animals 
raised by selective breeding according to their inclina-
tion to alcohol. 
Opioids
It is considered that opioid peptides participate in 
the etiology of alcoholism, as shown in clinical and 
experimental studies on animals. It was observed that 
the antagonists of opioid receptors (i.e. naltrexone) 
decrease alcohol intake. Drinking alcohol leads to the 
release of endogenous opioid peptides (endorphins) 
which activate the dopamine rewarding system40.It 
is supposed that individual differences in endorphin 
sensitivity underlay variation of craving for alcohol in-
tensity and therefore represent the risk of developing 
alcohol addiction41.
Neuropeptide Y 
Neuropeptide Y (NPY) is richly present in the 
structures representing the mesolimbic dopamine 
system (NAc, amygdala), while activation of the NPY 
receptors is connected with increased food intake and 
anxiolytic effects. It is considered that through these 
effects, NPY influences indirectly the intake of alco-
hol, and has been investigated as a potential alcohol 
intake modulator29. The mice in which the lack of 
NPY was induced by a molecular-genetic technique 
drank significantly more alcohol in the test of a will-
ing choice (two-bottle preference test), whereas the 
mice with stronger NPY gene expression showed 
lesser inclination to alcohol and greater sensitivity to 
its sedation effects42.
Subtypes of Alcoholism
Alcohol addiction is a public health problem and 
demands constant efforts in finding the mechanisms 
that lead to inappropriate behavior followed by social 
and labor dysfunctions43. The patients suffering from 
alcoholism represent a very heterogeneous group from 
the clinical, etiological and epidemiological points of 
view. The treatment of alcoholism is very difficult as 
the disease has frequent relapses, while strategies for 
its prevention generally prove inefficient.
Alcoholism has been recognized as a disease that 
is underlain by change in the neurobiological mecha-
nisms as a clear genetic basis, presuming that the 
diagnosis, if based on the symptomatology, must be 
heterogeneous as well. It has also been supposed that 
various medical agents would have variable thera-
peutic potential in particular patient subpopulations. 
As the issue of the clinically heterogeneous nature of 
the addiction was attempted to be solved during the 
last fifty years, various sub-classifications of patients 
were suggested. Such a division into subtypes has the 
purpose to assist in determination of targeted therapy 
when predicting the disease prognosis35,44,45. Clinical 
studies confirmed that classifying patients into more 
homogeneous groups would enable setting not only 
the most effective psychopharmacotherapy but appro-
priate psychotherapy treatment as well46.
The first classification of alcohol addicts was pub-
lished by Jellinek fifty years ago47, who classified pa-
tients into 5 subtypes according to the specific clinical 
qualities (signs of physical dependence, craving, toler-
ance and loss of control). 
Twenty years later, Cloninger et al. performed the 
first empirical adoptive study resulting in a dichotomy 
division of alcoholism based on patient characteris-
tics, dividing patients into those with type 1 and those 
with type 2 alcoholism addiction13.
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Type 1 alcohol addictive patients are those whose 
addiction is manifested later in life (after 25 years 
of age) and is characterized by a strong influence of 
external factors (social environment). Both sexes are 
equally represented and the patients tend to avoid 
damaging situations and excessive, hard drinking 
with bouts of abstinence from time to time. About 
two-thirds of alcohol addicts belong to this type and 
the disease has a slower course and better prognosis.
Type 2 are those addicts where the addiction 
emerges earlier in life (before 25 years of age), there 
is a strong genetic predisposition (family heredity, 
most often they are children of alcoholic parents). It 
is considered that type 2 patients are exclusively male 
patients who tend to antisocial (aggressive) behavior 
and drink in the first place for ‘enjoyment’ (and not for 
‘self-therapy’), they have no wish to avoid the damag-
ing consequences and cannot abstain. They often use 
other substances of addiction too. Such patients are as 
a rule more difficult to treat48.
According to Cloninger, the alcoholism subtypes 
also differ according to changes in the brain neu-
rotransmitter systems, proposing that type 1 alcohol-
ism patients have a stronger dopaminergic transmis-
sion deficit, while in patients with type 2 alcoholism 
dopaminergic transmission is not significantly dis-
turbed, but there is a significant defect of the seroton-
ergic transmission34. In such a way, he set the so-called 
neurobiological model of alcoholism. As it connects 
differences in the neurotransmission with differences 
in the personality, this model is often called the psy-
chological model of alcoholism.
The Cloninger neurobiological model was signifi-
cantly confirmed in recent years thanks to the neuro-
chemical, molecular-genetic, pharmacological stud-
ies, especially structural (MRI) and functional (PET, 
SPECT) brain screening49. Radiological studies, which 
tried to connect DA and SHT neurotransmission sys-
tems with some particular alcoholic subtypes, showed 
that type 1 had a decreased DA transmission followed 
by decreased DA transporter (DAT) density in the stri-
atum, while type 2 showed a lack of 5HT transmitter 
(5HTT), especially in the front cyngular cortex, dor-
sal striatum, dorsal amygdala limit and periventricular 
core of the hypothalamus50,51. As in type 1 the 5HT 
system changes also exist, but at a much lower extent, 
it is speculated that these changes are secondary to do-
paminergic changes, when compared with the 5HT 
system in type 2 already present at an early age35.
Next to Cloninger classification, there is another 
dichotomous division in the literature, proposed by 
Babor et al.52 which is, in essence, similar to Cloninger 
classification, arising from the theory of personality. 
When compared with Cloninger division, Babor’s di-
vision is based on the cluster analysis of 321 alcohol 
addicts, comprising various areas such as personality 
characteristics, comorbid psychiatric disorders, gravity 
of alcohol or other psychoactive substance intake, fam-
ily heredity of alcoholism, as well as the consequences 
and damages related to drinking. Taken all this into 
consideration, Babor et al. divide alcohol addicts into 
type A and type B, while the basic difference from 
Cloninger division is in the fact that Babor type B 
comprises addicts of both sexes, while Cloninger type 
2 consists exclusively of male patients. Such a patient 
classification has been tested in clinical studies.
A different approach to the classification of al-
coholism was suggested by Lesch et al.53,54. On the 
basis of a 5-year study including 444 patients, they 
suggested division into four categories based on fam-
ily heredity, psychopathology and hypothetical neu-
robiological basis. According to Lesch typology, the 
addicts type 1 (model of allergic reactions) have very 
strong abstinence difficulties and thus they drink in 
order to alleviate it. Recent studies point to an in-
creased glutamatergic neurotransmission in this group 
of patients55. Model type II (anxiety or conflict model) 
are addicts who drink alcohol for its anxiolytic effect 
with the purpose of self-medication. In addicts type 
III (depression model), the basic characteristic is the 
presence of affective disorders. Such patients drink al-
cohol as an antidepressant. Type IV (adaptation mod-
el) includes patients with pre-morbid brain damage, 
behavior disorder and significant difficulties in social 
functioning before age 14. A number of studies tried, 
with more or less success, to associate Lesch alcohol-
ism subtypes with some particular genetic and/or bio-
chemical parameters. For example, an increased pep-
tide level was recorded in type I and type II addicts 
that showed significant craving for alcohol. Results of 
a recent study show no connection between Lesch ty-
pology and certain polymorphisms in a number of DA 
and SHT gene systems investigated56.
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Apart from these sub-classifications of alcoholism 
most frequently cited in the literature, there also are 
others; however, in spite of great efforts invested to de-
fine clinical subtypes of alcoholism, which may bring 
about revision of the diagnostic criteria, none of the 
suggested classifications has shown any unambiguous 
results57. Therefore, attempts to classify alcoholism 
subtypes are continued with great patient populations 
and use of sophisticated statistical methods.
Personalities and Subtypes of Alcoholism
Current sub-classification of alcoholism is mostly 
based on patient personalities, their drinking profile 
and family heredity. In order to establish differences, 
the researchers rely on psychometric tests/question-
naires to evaluate the individual psychological char-
acteristics. Some of the questionnaires used in the 
typology of alcoholism research are Tridimensional 
Personality Questionnaire (TPQ ),  Treatment and 
Character Inventory (TCI), Eysenck Personality 
Questionnaire (EPQ ), Minnesota Multiphasic Per-
sonality Inventory (MMPI), Connecticut Typology 
Questionnaire (CTQ ), Neuroticism, Extraversion, 
Openness Personality Inventory (NEO-PI), etc.
Cloninger was the first to embark upon the re-
search of personality connections with biological 
factors in general and thereafter in alcoholism, spe-
cifically suggesting a psychological model of tem-
perament and character where the personality of each 
individual is represented by 3 basic dimensions of tem-
perament: seeking new excitements (novelty seeking, 
NS), avoiding damaging behavior (harm avoidance, 
HA), and dependence on reward (reward dependence, 
RD)48. The temperament dimension is a personality 
component which is hereditary, stable during devel-
opment, based on emotions, does not depend on social 
and cultural learning/experience, and is connected to 
the specific neurobiological characteristics.
Seeking new excitements/events (NS) is defined as 
compulsive necessity to have new excitements/events 
and must be undertaken regardless of the physical and 
social risks they bear. The assumption is that mesolim-
bic and mesofrontal dopaminergic projections are in-
cluded in the incentive action of this characteristic 
and that it is genetically given. Avoidance of harm-
ful behavior (HA, behavior inhibition) is a tendency 
towards an intensive answer to the aversive motives/
signs bringing about behavioral inhibition connected 
to the function of the serotonergic system and is thus 
assumed that the persons with a high HA result on 
the scale also have an increased release of serotonin 
from the presynapse and consequently a decreased 
number of postsynaptic serotonin receptors58. 
Dependence on reward (RD) is a tendency towards 
a strong reaction/answer to the reward and repeating 
the behavior which brought about this reward. It is 
considered that this dependence is connected to the 
noradrenergic function as it has been observed that 
persons with a low result on the RD scale have a de-
creased release of noradrenaline58.
The three given dimensions (NS, HA and RD) 
represent the basis for Cloninger’s Tridimensional Per-
sonality Questionnaire (TPQ ) and are used in the ar-
eas of neurobiology, psychology and psychiatry. Later 
on, Cloninger suggested an extended model including 
4 basic dimensions of temperaments, i.e. NS, HA, RD 
and persistence, as well as 3 dimensions of the charac-
ter, i.e. egocentricity (self-directedness), cooperativity 
(cooperativeness) and altruism (self-transcendence)34, 
making thus the basis of the 7-factor Temperament and 
Character Inventory (TCI) model. This model is also 
used when dividing the normal from the pathological 
behavior bringing about the occurrence of mental dis-
eases including alcoholism. As distinguished from the 
temperament dimensions, which are hereditary, it in-
cludes the unconscious learning and is connected with 
various neurotransmitting systems; character dimen-
sions within the mentioned models are connected to 
the psychology process and represent the function of 
the temperament, social learning, specific genetic fac-
tors and accidental events in life, developing gradually 
from the childhood till the grown up age. Different 
measuring scales, if compared, are overlapping to a 
great extent, i.e. TPQ scale with the NEO-PI scale 
shows that HA (TPQ scale) corresponds to neuroti-
cism (NEO-PI scale), while seeking for excitement 
(TPQ scale) corresponds to extrovert characteristic 
(NEO-PI scale)59,60. 
As already mentioned here, some personality 
characteristics are connected to changes in various 
neurotransmitting systems. Confirmation of the neu-
rochemical basis of differences between personality 
characteristics was received from various researches 
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including molecular-genetic, neurochemical (receptor 
bondage, peripheral models, brain screening, etc.) and 
pharmacological ones35,49.
Briefly, pursuant to the hitherto acquired knowl-
edge, it seems that in type 1 alcoholism an expressive 
characteristic of damage avoidance (HA) is present, 
as well as a decreased DA transmission and increased 
SHT transmission, whereas type 2 alcoholism is char-
acterized by seeking excitement (NS), unchanged DA 
transmission and decreased SHT transmission. These 
neurochemical differences between the subtypes of 
alcoholism represent the basis for different therapeutic 
approach to these patients. 
Genetic Basis of Alcohol Addiction
Results of numerous family studies, twin studies 
and adoptive studies point to the fact that alcoholism 
addiction is hereditary in more than 50% of cases5,7,31, 
and, even more, the alcohol intake model itself is 
hereditary as well (alcohol quantity, frequency of in-
toxication, etc.)8,36. Thus, exposure to alcohol changes 
the expression of different genes in the human brain 
and in experimental animals6,9. The model of alco-
holism inheritance has not yet been fully clarified, 
however, it is supposed that the disease is connected 
to a larger number of genes (polygenetic) included in 
neurotransmission, cell mechanisms (i.e. intracellular 
signalization, cell response to stress, etc.) and the gen-
eral metabolic functions (metabolism of alcohol, lipid 
metabolism, etc.), with simultaneous influence of the 
environment and the interaction of the genes and the 
environment6,10. 
A strong inheritance component concerning al-
coholism speaks for the existence/inheritance of the 
functional variances of the genes participating in the 
alcohol metabolism, neurobiology of reward, cogni-
tive functions, etc.7.
One of the most frequent forms of the genetic 
basis of alcoholism are association studies assessing 
whether a connection exists between a certain geno-
type or allele in the candidate gene and a specific phe-
notype (within the family or in relation to the healthy 
population).
Of the genes included in the neurotransmitting 
systems, the most researched ones are the genes cod-
ing GABA-A and GABA-B receptors, dopamine 
D2 receptors, dopamine transporter, serotonin trans-
porter, and serotonin 5HT-1B, -2A and 2C receptors; 
however, in all cases, the results of various studies are 
not consistent10,36. One of the reasons for this is surely 
the great heterogeneity of patients considering their 
addiction grade, comorbidity, craving, etc. As already 
mentioned herein, it has been assumed for long now 
that the contribution of genetic factors is stronger in 
some types of alcoholism13,14.
In the last years, in our research of alcoholism we 
have come across studies investigating the function of 
a certain alcoholism subtype with the occurrence of 
polymorphisms in the genes coding the synaptic pro-
teins included in the development of alcoholism. So, 
a connection was observed between alcoholism type I 
and the polymorphic variant (position -602 in region 
5) of the NPY gene. It is considered that this gene 
has a role in the anxiety regulation. Polymorphism 
in the gene for serotonin transmitter, responsible for 
its lower activity (s-form 5HTTLPR polymorphism) 
is connected to alcoholism type 2 but also to the 
characteristics such as aggressiveness and antisocial 
behavior5,62.
Neuropharmacological Treatment of Alcoholism
Alcoholism, in addition to the clear psychosocial 
component, is in its basis a brain disease. The use of 
pharmacotherapy enforces the psychosocial treatment 
effects and improves significantly therapeutic effect.
Fundamental and clinical research of alcoholism 
has shown that several brain transmitter systems have 
an important role in the etiology of addiction. This 
has facilitated considerably and directed the develop-
ment of specific pharmacotherapy. Unfortunately, the 
pharmacotherapeutic effect of medications is generally 
speaking rather modest, although it is to a great extent 
present in various clinical studies. Of the medications 
we use today we shall mention a few. 
Naltrexone is an antagonist of the (mu) and (e 
kappa) opioid receptor. Its basic pharmacological ef-
fect on the intake of alcohol relates to the blockade 
of the opioid receptors connected with the intake of 
alcohol, as well as modulation of the neurotransmit-
ters connected to the opioid system. It is used in the 
addiction treatment of opiates and alcohol in a daily 
dose of 5 mg. Although most studies showed a rather 
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poor pharmacotherapeutic effect, persons with certain 
clinical characteristics such as strong craving for alco-
hol and family history of alcoholism respond well to 
naltrexone63. Some authors describe greater efficacy of 
naltrexone in the Babor alcohol addict type A, while 
others say the same for Cloninger type 264,65.
Acamprosate is a glutamate receptor NMDA an-
tagonist assisting in maintenance of abstinence, acting 
in such a way that the balance between the excitation 
(glutamate) and inhibition (GABA) neurotransmis-
sion is established again after being disturbed by 
chronic intake of alcohol. Results of clinical studies 
testing the pharmacotherapy effects of acamprosate 
are very different. While some authors, especially in 
Europe, show clear efficacy, the opinions in the USA 
vary66,67. Thus, different effects of acamprosate were 
shown in various subtypes of alcoholism. For exam-
ple, the application of acamprosate prolonged the ab-
stinence period in Lesch type I and type II patients, 
whereas no positive effects were recorded in type III 
and type IV patients68.
Selective inhibitors of the serotonin return intake 
(selective serotonin reuptake inhibitors, SSRIs) act in 
such a way that they increase the serotonin presence 
in the synaptic fissure, thus increasing the seroton-
ergic neurotransmission. Clinical studies in various 
animal models have consistently demonstrated that 
SSRI reduced the intake of alcohol; however, the 
clinical fact is much less clear. The assumption is that 
the application of functionally different serotonergic 
agents (SSRI antagonist receptors, etc.) may lead to 
different effect in different subtypes of alcoholism33. 
Of SSRIs, the pharmacotherapy effect of fluoxetine 
was studied, as it shows affinity for 5-HT2 receptors 
and could thus influence the craving and impulsive-
ness in type B and type 2 alcoholism. Contrary to 
expectations, fluoxetine was even less effective in 
this type of alcoholism, except for cases with comor-
bid anxiety disorders or mood disorders69. Another 
SSRI, sertraline, was shown to have effect in type 
A addicts, whereas no effect was observed in type B 
alcoholism70. Accordingly, one may say that SSRI did 
not show any efficiency if the group of tested patients 
was heterogeneous but it may be of use in personal-
ized pharmacotherapy.
Ondansetron is a selective antagonist of the 5-HT3 
receptor. The brain 5-HT3 receptors are ionic canals 
alcohol may bind on and they participate in the alco-
hol effect modulation via interaction with dopamine. 
The blockade of the 5-HT3 receptor weakens the re-
lease of dopamine and, as proven in animals, decreases 
alcohol intake38.
A double blind, placebo controlled study that 
included 271 alcohol addicts showed that ondanse-
tron decreased the intake of alcohol and prolonged 
the abstinence period in type B patients, whereas no 
positive ondansetron effect was observed in type A 
patients45,69.
Disulfiram is a drug which, unlike those described 
above, does not act on neurotransmission, has been in 
use since 1940, and most probably still is the most fre-
quently used drug in alcoholism therapy, both in the 
world and in our clinical practice. The mechanism of 
disulfiram effect is metabolic ALDH inhibition caus-
ing the accumulation of acetaldehyde in blood and, 
consequently, leading to unpleasant effects (sweating, 
headache, vomiting and similar) if the intake of alco-
hol is continued. Disulfiram has no effect on craving 
for alcohol and the patient must be very motivated to 
take disulfiram on his/her own free will.
When choosing therapy, an important aspect is 
the previously mentioned fact that some persons do 
have predisposition against alcohol. It is to be ex-
pected that such persons will benefit from a precisely 
specific therapy directed toward the disorders under-
lain by their vulnerability against alcoholism. This 
would be important when we speak of recognizing 
the individuals, children and/or adults who are more 
vulnerable when we speak of alcohol, when variations 
in some neurobiological areas should be taken in con-
sideration. This is also the reason why the gene can-
didates are studied and why personality studies are 
being conducted.
The clinical purpose of establishing the alcoholism 
subtypes is precisely to set the process in behavioral 
and pharmacological therapy which may best help a 
particular individual. Therapy individualization is 
especially important when we speak of serotonergic 
medications, where the SSRIs are more effective in 
type I/A patients and antagonists of 5HT3 receptors 
in type 2/B alcoholism.
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Monoamine Oxidase (MAO)
Classification, distribution and role of MAO
The enzyme monoamine oxidase (MAO, E.C1. 
4.3.4.) is an integral protein of the external mito-
chondrion membrane acting as a catalyst for oxidative 
deamination in the brain and peripheral tissue, con-
trolling in such a way their concentration. It occurs in 
two forms, MAO-A and MAO-B, which differ ac-
cording to molecular mass, affinity for substrates and 
sensitivity of its inhibitors. 
The isoenzyme A acts as a catalyst for the break-
down of the larger endogenous amine neurotrans-
mitters such as serotonin, noradrenaline and adrena-
line, and shows higher sensitivity for the irreversible 
inhibitor clorgiline, whereas the isoenzyme B breaks 
down primarily small endogenous and exogenous 
amines such as benzylamine and beta-phenyleth-
ylamine because it is sensitive to the irreversible in-
hibitors pargyline and deprenyl. Both MAO types 
have an equal affinity towards dopamine amine and 
tryptamine. Specific quality of isoenzyme against 
the substrate is determined with the aliphatic and 
aromatic side branches of amino acids at an active 
site. Depending on the substrate concentration, 
both isoenzymes may metabolize all the mentioned 
substrates. The presence of MAO was proven in al-
most all tissues, whereby the MAO-A and MAO-B 
differ according to their distribution in tissues and 
localization in the cells. The highest concentra-
tion of both isoenzymes is found in the liver, while 
greater MAO levels are present in the spleen, small 
intestine, lungs, kidneys and adrenal gland. Hu-
man placenta also has high MAO-A contents, while 
MAO-B form is found mostly in platelets and lym-
phocytes70. A high level of MAO is found in human 
brain, as shown by catecholaminergic neurons (nora-
drenergic, adrenergic and dopaminergic), especially 
in the NA-core locus coeruleus, while MAO-B is 
mostly present in serotonergic neurons (especially in 
the raphe cores), histaminergic neurons, glial cells 
and ependymal cells. The MAO-A distribution in 
brain reflects the distribution of the natural enzyme 
substrates, while the possible role of MAO-B se-
rotonergic neurons is to prevent the accumulation 
of various substrates that may interfere with 5-HT 
metabolism.
Isoenzyme MAO-A and MAO-B structure
The amino acid sequence of the MAO-A and 
MAO-B in humans has been known for some 20 
years71. Isoenzymes A and B are composed of 527 
and 520 amino acids, their molecular mass is 59700 
and 58000, respectively, and they show 70% of iden-
tical amino acid sequences. Both sequences contain 
pentapeptide Ser-Gly-Gly-Cy-Tyr covalently con-
nected to the coenzyme flavin adenine dinucleotide 
(FAD)72.
The primary structure of both MAO isoenzymes 
consists of three regions, i.e. a region in the amino 
end vicinity, so-called Rossmann fold,  an area that 
non-covalently binds FAD; a region responsible for 
the specific quality (located in the middle of the en-
zymes); and the area binding FAD. Besides these 
regions, at the very carboxy-end of the enzyme is 
an essentially hydrophobic region the role of which 
would be to ensure fixing of proteins in the external 
membrane of the mitochondrion or it may represent 
the signal for its direction. Difference in the catalyst 
activity of MAO-A and MAO-B is the consequence 
of difference in their amino acid sequences70.
MAO-A and MAO-B gene structure
Isoenzymes MAO-A and MAO-B originate from 
two separate genes located on the shorter X chromo-
some branch in the region Xp 11.23-11.4. The length 
of both genes amounts to 60 to 70 kb, both are com-
posed of an equal number of exons (n=15) and both 
have the same exon and intron organization, suggest-
ing that they have emerged by duplication of the same 
progenitor gene. Both MAO amino acid sequences in 
humans and rats show 88% conformity72.
Significant differences between MAO-A and 
MAO-B genes exist in transcription elements in pro-
moter organizations and precisely these differences 
are responsible for various tissue and cell expression 
of individual enzyme, especially when bound to the 
catecholaminergic and serotonergic brain neurons70,73.
In the past twenty years, owing to development 
of the molecular-genetic technique, a large number 
of polymorphic sites in the genes for MAO-A and 
MAO-B have been detected. The gene represents a 
sequence of nucleotides placed in a special position 
on the chromosome (locus). The genes located on the 
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same loci on homologous chromosomes are called 
alleles and they supervise always the same pheno-
type characteristic. One pair of alleles on a certain 
locus represents an individual genotype and these 
alleles can also be identical (the individual is a ho-
mozygote for a certain characteristic) or they may 
differ (a heterozygote for this characteristic). There 
are natural variations in all genes and if one variation 
appears in at least 1% of the population it is called 
polymorphism. The most frequent polymorphism 
forms we encounter are substitutions of one nucle-
otide basis (single nucleotide polymorphism, SNP), 
double sequence of a certain number of base pairs, 
and insertion/deletion of DNA segment from cer-
tain base pair numbers.
The following polymorphic gene locations for 
MAO-A are described in the literature: variable 
number of tandem repeats (VNTR) polymorphism in 
the promotor gene consisting of a various number of 
repeats (3, 3.5, 4,5) of the sequence of 30 base pairs 
whose presence influences the transcription activity/
functionality; VNTR in intron 1; a highly polymor-
phic microsatellite repeating sequence (CA)n in intron 
2; several point mutations (SNPs) in the coded region 
bringing the synthesis of imperfect protein, and oth-
ers. In the gene for MAO-B, three polymorphic loca-
tions have been detected: C -1, 114T polymorphism 
in promoted (GT)n repeated sequence (n=18-29) in 
intron 2, and A/G dimorphism in intron 13.
The presence of a certain polymorphism within a 
gene or a combination of several polymorphisms on 
one or different genes may contribute to inter-indi-
vidual differences in the personality of an individual 
and vulnerability to a certain disease including alco-
holism, as well as differences in pharmacotherapeutic 
response. MAO is the best investigated VNTR poly-
morphism in the gene promoter for MAO-A whose 
presence has greatest influence when we speak of the 
transcription activity/functionality.
MAO and the platelet model
Platelets are small nuclear blood cells participat-
ing in keeping the blood vessel system integrity and 
possess a few serotonin elements showing biochemical 
and pharmacological similarities with the analog ele-
ments in the serotonergic neurons. This similarity of 
the platelets with neurons, as well as easy accessibility 
of the platelets in vivo makes them an appropriate pe-
ripheral model for serotonergic mechanism research 
in neurobiology and biologic psychiatry.
The human platelet serotonin system includes 
dense granules with stored serotonin, serotonin trans-
porter (5HTT) and serotonin 2A (5HT-2A) recep-
tor on the platelet membrane, and the mitochondrial 
enzyme MAO. All three platelet proteins are bound 
to the serotonin system 5HT, 5HT-A receptor and 
MAO and are, structurally, equal to the brain ones, 
coded with the same genes, a fact also speaking for 
the use of platelets as a model in neurobiology. One 
should, however, mention the fact that there are 
rather contradictory opinions regarding the value of 
platelet model; namely, it has been demonstrated that 
there is no correlation between the brain and plate-
let MAO-B activity, thus pointing to their different 
regulation. Unlike this, however, central MAO and 
platelet MAO values show very good correlation after 
pharmacological inhibition. 
The platelet MAO activity follows the Michaelis-
Menten enzyme kinetics.  Kinetic parameters Vmax 
(enzyme catalyst reaction speed measure) and Km 
(enzyme affinity towards substrate indicator) depend 
on the substrate and are calculated from the enzyme 
saturation curve resulting from measuring the reac-
tion speed catalyzed with enzyme within a certain 
time period with various substrate quantities and a 
constant enzyme quantity in the incubation mixture. 
Healthy humans have a very wide platelet MAO ac-
tivity span and these values vary to up to 50 times74. 
It is considered that this may be the consequence of 
endogenous factors (age, sex, genetic variations, hor-
monal status, circadian rhythm), as well as of exog-
enous factors such as medication, diet and various 
pathologic conditions of the body. It has also been 
observed that female individuals have higher enzyme 
values, while MAO-B activity increases with aging. 
It is also considered that platelet MAO-B activity is 
stable over time and genetically stipulated.
Although currently there are differences in the 
opinions with regard to the platelet model value, the 
possibility of its use in neurobiology and biologic psy-
chiatry is still under research owing to the benefits we 
experience from the peripheral indicator of the brain 
activity.
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Psychological role of MAO and clinical implications
The primary role of MAO in the brain is oxida-
tive deamination of the neurotransmitting amine 
catalysis, i.e. serotonin, adrenaline, noradrenaline 
and dopamine; thus, this enzyme is the key factor 
in maintaining cytoplasmic concentrations of vari-
ous neurotransmitters and regulation of the neu-
rotransmitting synaptic activity. MAO also acts as 
an amine ‘cleaner’ as such amines are usually found 
in low concentrations (tyramine, phenylethylamine) 
and participates in the breakdown of the exogenous 
inert amines and their derivatives. It is also consid-
ered to prevent accumulation of natural substrates 
(i.e. dopamine) which may interfere with serotonin 
metabolism75.
In peripheral tissues such as the liver, intestines or 
lung, MAO has a protective function as it oxidizes the 
amines from the blood or prevents their entering the 
circulation70,75. MAO activity differs according to sex, 
and concentrations of MAO-A and MAO-B in the 
brain change in a different way during life. MAO-A 
appears ontogenetically earlier and at the moment of 
birth its level equals those throughout life with the 
exception of a temporary rise in the early postnatal 
time period. As opposed to this, the MAO-B concen-
tration in the brain increases several times after birth, 
probably owing to strong astrocyte proliferation, and 
then it remains relatively stable until the 60ies, when 
it starts rising again, probably due to proliferation of 
glial cells as a substitute for declining neurons75.
Taken its function into consideration, MAO is the 
enzyme included in the etiology and pathogenesis of 
various neuropsychiatric and neurological diseases. 
Numerous experimental and clinical studies point to 
the role of MAO in depressive and anxiety disorders, 
neurologic diseases, Parkinson’s disease, Alzheimer’s 
disease), addictive diseases, etc. Selective MAO in-
hibitors are primarily used in the treatment of de-
pression and have their indication area also in anxi-
ety disorders, panic condition, social phobias, panic 
situations, bulimia and migraine, whereas selective 
MAO-B inhibitors are used in neurology for Parkin-
son’s and Alzheimer’s disease therapy76.
The assumption that a lowered MAO may be an 
indicator of vulnerability to certain psychiatric dis-
eases is more than 30 years old and, as opposed to 
the brain, platelets are easily accessible. Many clini-
cal studies used platelets as a peripheral model in this 
enzyme research.
Monoamine Oxidase and Alcoholism Subtypes 
Platelet MAO-B and alcohol addiction 
The finding of decreased platelet MAO-B activ-
ity in various psychiatric diseases and disorders has 
brought about the assumption than this enzyme may 
be a genetic indicator (trait marker) or a disease condi-
tion indicator (state marker) in biologic psychiatry.
However, most recent results point to the fact that 
the lowered enzyme activity is not directly connected 
to the disease phenomenon concerning a number of 
diseases but is connected to various personality char-
acteristics which, again, represent a risk factor in the 
emergence of various diseases and disorders77,78.
Since the mid-1970s, a large number of researches, 
although not all of them, point to the fact that a de-
creased platelet MAO-B activity was observed in in-
dividuals addicted to alcohol, in particular those diag-
nosed with the sub-categorized type 2 alcoholism79,80. 
The lowered platelet MAO-B activity was found to 
be associated with certain characteristic traits such as 
impulsiveness, lack of adaptation, avoidance of monot-
ony and seeking for excitement81. It is also connected 
to positive characteristics such as creativity, boldness, 
leadership and management ability82. However, it 
should also be noted that some of the studies did not 
establish any connection between lowered MAO-B 
activity and alcohol addiction, whereas some authors 
did observe transitory increase in the early phase of 
alcohol abstinence83,84.
Also, some thirty years ago, a direct inhibitory ef-
fect of cigarettes on platelet MAO-B activity was ob-
served but the smoker status of the study individuals 
was rarely taken in consideration until recently. The 
finding, however, reached by the positron emission 
tomography (PET) technique speaking for a signifi-
cantly decreased MAO-B activity in the brain and all 
peripheral tissues made many research results in al-
cohol addicts also known as heavy smokers question-
able. 
In recent years, several authors investigated the 
association of MAO-B, smoking and alcohol but 
even then the results were not unambiguous. While 
some studies taking smoking habit of the study indi-
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viduals in consideration report no changes of MAO 
activity in alcoholic patients, others report on such 
differences85,86. One of many explanations is that study 
populations were not homogeneous, as the authors in 
most cases did not divide patients into alcoholic sub-
types.
As in the cases of the MAO-B platelet association 
with psychiatric diseases and disorders, one should 
also revise the results of its connection with psycho-
logical parameters/personality characteristics since 
these studies did not take the study population smok-
ing habit into consideration either. The research where 
the authors controlled smoking and other factors in 
order to find out whether it may affect the MAO ac-
tivity speaks for the fact that the enzyme connection 
with some of the personality dimensions actually does 
exist87.
Polymorphic gene variant for MAO-B and alcohol 
addiction
One of the polymorphisms in the gene coding 
MAO-B is the A/G dimorphism (A644G) in intron 
13. This polymorphism is actually a point mutation, 
where one base is exchanged by another (A or G) and 
is located on 36 bases upstream from the intron 13 and 
exon 14 border. The existence of this polymorphism 
will not lead to change in the amino acid sequence in 
the protein but is still involved in the gene transcrip-
tion regulation and the quantity of enzyme molecules. 
The in vitro studies show that intron 13 has a very 
strong inscription activity, higher with the G- than 
A-alleles88. Some authors observed that the platelet 
MAO-B activity is also higher in healthy male indi-
viduals carrying G allele in comparison to those with 
A-allele. We assume that this polymorphism is inher-
ited together with another one influencing thus the 
protein structure or any other transcription regulation 
and the synthesized protein89. As opposed to these 
findings, other authors did not show any association 
between the enzyme activity and the genotype90. The 
results point to different tissue-specific control mech-
anisms of the MAO-B activity in the platelets and in 
the brain.
The MAO-B A/G dimorphism has been mostly 
researched in Parkinson’s disease, where the connec-
tion between the A allele and early disease develop-
ment was demonstrated, yet again, not in all studies91. 
A combination of genotypes within the genes for 
MAO-B and for dopamine D2 receptor is connected 
with smoking in humans92. The connection of the A/G 
dimorphism with some personality characteristics has 
hitherto not been observed93. We also presume that 
the connection between this genetic variance and a 
particular phenotype is sex dependent94, a fact also 
considered important in pharmacotherapy.
Considering the association with alcohol addiction, 
there are several studies researching the connection of 
polymorphisms in the genes coding MAO and alco-
holism, but they refer primarily to the VNTR poly-
morphism in the regulator gene region for MAO-A, 
where it is considered to influence the enzyme activ-
ity/functionality transcription. It seems that an al-
lele with 3 repeats and a lower transcription activity 
represents the risk allele for vulnerability to alcohol-
ism, primarily with regard to the antisocial form and 
antisocial behavior type when under alcohol intoxica-
tion in general and in connection of the genotype and 
the phenotype has been modulated with psychosocial 
conditions; a significantly stronger connection was re-
corded in the individuals that had been abused sexu-
ally or in childhood95,96. Some studies also took the 
type of alcoholism in consideration, but difference be-
tween these types was either not shown at all or only a 
higher presence of 3-repeat allele was recorded in type 
2 alcoholism97,98. According to some results, it seems 
that MAO-A genotype is a better prognostic indica-
tor for smoking intensity in the individuals addicted 
to alcohol who are very heavy smokers99.
Although the MAO-B activity is genetically stip-
ulated, so that even 70% of its variable activity may 
be explained by inheritance, the research related to 
the MAO-B genotype and different psychiatric dis-
eases, as well as the personalities connected to a cer-
tain disease are much less represented and there are 
almost none in alcoholism. Our preliminary studies 
performed in a small number of individuals did not 
show differences in the MAO-B genotype between 
the patients suffering from alcoholism and control 
population100. A study in a small number of female 
patients addicted to alcohol revealed that, as opposed 
to MAO-A, the MAO-B haplotype was connected 
to alcoholism independently of the antisocial behav-
ior 95.
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Sažetak
NEUROBIOLOŠKE OSNOVE OVISNOSTI O ALKOHOLU
A. Matošić, S. Marušić, B. Vidrih, A. Kovak Mufić i L. Čičin-Šain
Ovisnost o alkoholu predstavlja heterogeni psihijatrijski poremećaj po svojoj etiologiji i fenotipu. Razlike u fenotipskim 
karakteristikama se ogledaju u dobi nastanka ovisnosti, alkohološkoj anamnezi, odnosno povijesti pijenja, komorbidnim 
poremećajima i nastanku apstinencijskih smetnji. Što se tiče etiologije alkoholizma, smatra se kako bolest nastaje kao po-
sljedica međusobnog djelovanja okruženja i genetskih čimbenika. Brojnim istraživanjima tijekom posljednjih nekoliko de-
setljeća upoznati su mnogi aspekti biokemijske, stanične i molekularne podloge ovisnosti o alkoholu, što je dovelo do toga 
da se alkoholizam kao i druge ovisnosti danas smatra moždanom bolesti. Prepoznavanjem alkoholizma kao bolesti koja u 
svojoj osnovi ima promjene neurobioloških mehanizama, kao i jasnu genetsku podlogu, pretpostavljeno je i da je dijagnoza 
bazirana samo na simptomatologiji, u osnovi heterogena. Kako bi se pokušao riješiti problem klinički heterogene prirode 
ovisnosti tijekom proteklih pedesetak godina predložene su različite subklasifikacije bolesnika. Prema Cloningeru podti-
povi alkoholizma razlikuju se i s obzirom na promjene u moždanim neurotransmiterskim sustavima pa tako pretpostavlja 
da bolesnici tipa 1 alkoholizma imaju jače deficitarnu dopaminergičnu transmisiju, dok kod bolesnika tipa 2 alkoholizma 
dopaminergična transmisija nije znatnije poremećena, ali je prisutan značajan nedostatak serotonergične transmisije. Time 
je utemeljio tzv. neurobiološki model alkoholizma. Kako razlike u neurotransmisiji povezuje i s razlikama u osobnosti/
crtama ličnosti taj model naziva se i psihobiološki model alkoholizma. Kod tipa 1 alkoholizma prisutna je izražena osobina 
izbjegavanja štete (HA), smanjena transmisija dopamina i povišena serotoninska transmisija, dok tip 2 alkoholizma ima 
izraženu osobinu traženja uzbuđenja (NS), nepromijenjenu dopaminsku (DA) transmisiju i smanjenu  serotoninsku (5HT) 
transmisiju. Navedene neurokemijske razlike među podtipovima alkoholizma čine osnovu za drugačiji terapijski pristup 
bolesnicima. Pijenje alkohola mijenja ekspresiju različitih gena u mozgu čovjeka. Model nasljeđivanja alkoholizma nije 
jasan, no smatra se da je bolest povezana s većim brojem gena (poligenska) uključenih u neurotransmisiju, stanične meha-
nizme i opće metaboličke funkcije uz istodobni utjecaj okoliša. Doprinos genetičkih čimbenika jači kod određenih tipova 
alkoholizma te se posljednjih godina u istraživanjima alkoholizma susreću studije koje istražuju povezanost pojedinog 
podtipa alkoholizma s pojavom polimorfizama u genima koji kodiraju sinaptičke proteine uključene u nastanak alkoho-
lizma. Primarna uloga monoaminoksidaze (MAO) u mozgu je katalizacija oksidativne deaminacije neurotransmiterskih 
amina – serotonina, adrenalina, noradrenalina, dopamina, i stoga taj enzim predstavlja ključni čimbenik u održavanju 
citoplazmatske koncentracije različitih neurotransmitera, odnosno u regulaciji neurotransmiterske sinaptičke aktivnosti. 
Obzirom na svoju funkciju, MAO je enzim koji je uključen u etiologiju i patogenezu različitih neuropsihijatrijskih i ne-
uroloških bolesti. Nalaz snižene aktivnosti trombocitne MAO-B u različitim psihijatrijskim bolestima doveo je do pret-
postavke da taj enzim može biti konstitucijski/genetički pokazatelj (trait marker) ili pokazatelj stanja bolesti (state marker) 
u biološkoj psihijatriji. Vezano uz ovisnost o alkoholu, postoji više studija koje su istraživale povezanost polimorfizama u 
genima koji kodiraju MAO i alkoholizma, no one se prvenstveno odnose na VNTR polimorfizam u regulatornoj regiji 
gena za MAO-A za koji se smatra da utječe na transkripcijsku aktivnost/funkcionalnost enzima. 
Ključne riječi : Alkoholizam – genetika; Alkoholizam – patofiziologija; Genetska predispozicija za bolest; Monoamino oksida-
za – krv; Fenotip; Polimorfizam, genetski
